Category: 112457-95-1

Clinical observation of dexzopiclone combined with tandospirone citrate in treatment of patients with hypertension complicated with anxiety was written by Wang, Na;Liu, Hua-ling. And the article was included in Linchuang Huicui in 2013.Application In Synthesis of rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate This article mentions the following:

Objective: To observe the therapy effect of dexzopiclone combined with tandospirone citrate in treatment of patients with hypertension complicated with anxiety. Methods: 120 patients with hypertension complicated with anxiety were randomly divided into group A (40 cases), group B (40 cases) and group C (40 cases). The patients in group A administrated lacidipine, and the patients in group B administrated tandospirone citrate and lacidipine. The patients in group C administrated dexzopiclone, tandospirone citrate and lacidipine. SBP, DBP and Hamilton anxiety scale (HAMA) were observed before therapy and 8 wk after therapy. Results: Before therapy, the difference in SBP, DBP and HAMA score had no statistical significance among the three groups. After therapy, SBP, DBP and HAMA score in group B and group C had obvious decrease as compared with before therapy (P < 0.05 or P < 0.01). After therapy, SBP and DBP in group B and group C were lower than in group A (P < 0.01). The DBP in group C was lower than group B (P < 0.01). The HAMA score in group C after therapy was lower than in group A and group B (P < 0.01). The difference in adverse reaction had no statistical significance among the three groups (χ² = 0.721, P > 0.05). Conclusion: Hypertension has close correlation with anxiety and insomnia, and in clin. working, we not only need to pay attention to control of hypertension and also need to change the psychol. disease and complicated related symptom of patients to well control blood pressure, prevent target organ injury and improve survival rate. In the experiment, the researchers used many compounds, for example, rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate (cas: 112457-95-1Application In Synthesis of rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate).

rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate (cas: 112457-95-1) belongs to piperazine derivatives. Industrial applications of piperazine include the manufacture of plastics, resins, pesticides and brake fluids. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successful. Application In Synthesis of rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Analysis of Risk Factors in Human Bioequivalence Study That Incur Bioinequivalence of Oral Drug Products was written by Yamashita, Shinji;Tachiki, Hidehisa. And the article was included in Molecular Pharmaceutics in 2009.Recommanded Product: 112457-95-1 This article mentions the following:

In the study of human bioequivalence (BE), newly developed oral products sometimes fail to prove BE with a reference product due to the high variability in pharmacokinetic (PK) parameters after oral absorption. In this study, risk factors that incur bioinequivalence in BE study were analyzed by applying the Biopharmaceutics Classification System (BCS). Forty-four generic products were selected from a database of BE studies in the past 10 years at Towa Pharmaceutical Co., Ltd. (Osaka, Japan), and 90% confidence interval (CI) of AUC and C_max in human BE study for all products were converted into coefficient of variation (CV₉₀). Then, the required number of subjects to confirm BE was estimated from the 90% CI in human BE study of new products. It was found that both the permeability of drugs to human intestinal membrane (P_eff) and the dose number calculated from their water solubility did not correlate well to CV₉₀ and the estimated subject number in human BE study, suggesting the contribution of other factors to cause the variability in oral drug absorption. As the PK parameter of drugs, the value of AUC/dose was calculated and plotted against CV₉₀ and the estimated subject number by classifying drugs into 4 BCS classes. For drugs in classes 1 and 3, AUC/dose gave a clear criterion to distinguish the drugs with a high risk of bioinequivalence, where drugs with low AUC/dose showed high CV₉₀ and large number of subjects. It was suggested that the high metabolic clearance (for class 1 drug) and low oral absorption (for class 3 drug) could be significant factors to incur bioinequivalence in human BE study, although for drugs in classes 2 and 4, clear factors were not defined. Consequently, for drugs in BCS classes 1 and 3, risks in human BE study to incur bioinequivalence could be predicted by calculating the AUC/dose. In the case of generic drugs, since the parameter of AUC/dose is available before initiating human BE study, this finding is expected to promote an efficient and cost-saving strategy for the development of oral drug products. In the experiment, the researchers used many compounds, for example, rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate (cas: 112457-95-1Recommanded Product: 112457-95-1).

rel-(3aR,4S,7R,7aS)-2-(4-(4-(Pyrimidin-2-yl)piperazin-1-yl)butyl)hexahydro-1H-4,7-methanoisoindole-1,3(2H)-dione 2-hydroxypropane-1,2,3-tricarboxylate (cas: 112457-95-1) belongs to piperazine derivatives. Piperazine is a fairly basic compound and is an amine solvent. Piperazine is formed as a co-product in the ammoniation of 1,2-dichloroethane or ethanolamine. These are the only routes to the chemical used commercially.Recommanded Product: 112457-95-1

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics